Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease

Neurology

Volumn 68, Issue 4, 2007, Pages 254-261

  Lonser, R R ^a   Schiffman, R ^a   Robison, R A ^a   Butman, J A ^b   Quezado, Z ^b   Walker, M L ^d   Morrison, P F ^c   Walbridge, S ^a   Murray, G J ^a   Park, D M ^a   Brady, R O ^a   Oldfield, E H ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; GLUCOSYLCERAMIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; BRAIN; BRAIN STEM; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVECTION ENHANCED DELIVERY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MONITORING; DRUG TARGETING; EVALUATION; FRONTAL LOBE; GAUCHER DISEASE; HUMAN; IN VIVO STUDY; INFANT; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIMATE; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; CONVECTION; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; INFANT; MACACA MULATTA; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; SURGERY, COMPUTER-ASSISTED;

EID: 33846464968     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000247744.10990.e6     Document Type: Review

References (31)

1. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-1470.
2. Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N Engl J Med 1974;291:989-993.
3. Brady RO. Therapy for the sphingolipidoses. Arch Neurol 1998;55:1055-1056.
4. Altarescu G, Hill S, Wiggs E, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 2001;138:539-547.
5. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-119.
6. Lonser RR, Walbridge S, Garmestani K, et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 2002;97:905-913.
7. Nguyen TT, Pannu YS, Sung C, et al. Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg 2003;98:584-590.
8. Lonser RR, Walbridge S, Murray GJ, et al. Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann Neurol 2005;57:542-548.
9. Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab 1997;17:713-731.
10. Langer R. New methods of drug delivery. Science 1990;249:1527-1533.
11. Morrison P. Distribution models of drug kinetics. In: Atkinson AJ Jr, Dedrick RL, et al, eds. Principles of clinical pharmacology. New York: Academic Press, 2001:93-112.
12. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975;195:73-83.
13. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91:2076-2080.
14. Lonser RR, Gogate N, Morrison PF, Wood JD, Oldfield EH. Direct convective delivery of macromolecules to the spinal cord. J Neurosurg 1998;89:616-622.
15. Lonser RR, Weil RJ, Morrison PF, Governale LS, Oldfield EH. Direct convective delivery of macromolecules to peripheral nerves. J Neurosurg 1998;89:610-615.
16. Laske DW, Morrison PF, Lieberman DM, et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 1997;87:586-594.
17. Brady RO, Kanfer JN, Bradley RM, Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest 1966;45:1112-1115.
18. Verity MA, Montasir M. Infantile Gaucher's disease: neuropathology, acid hydrolase activities and negative staining observations. Neuropadiatrie 1977;8:89-100.
19. Frederickson DS, Sloan HR. Glucosyl ceremide lipidosis: Gaucher's disease. In: Stanbury JB, Wyngaarden JB, Frederickson DS, eds. The metabolic basis of inherited disease. 3rd ed. New York: McGraw-Hill, 1978:730-759.
20. Mignot C, Doummar D, Maire I, De Villemeur TB. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev 2006;28:39-48.
21. Bembi B, Ciana G, Zanatta M, et al. Cerebrospinal-fluid infusion of alglucerase in the treatment for acute neuronopathic Gaucher's disease. Pediatr Res 1995;38:A425.
22. Barranger JA, Rapoport SI, Fredericks WR, et al. Modification of the blood-brain barrier: increased concentration and fate of enzymes entering the brain. Proc Natl Acad Sci USA 1979;76:481-485.
23. Zirzow GC, Sanchez OA, Murray GJ, Brady RO, Oldfield EH. Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain. Neurochem Res 1999;24:301-305.
24. Croteau D, Walbridge S, Morrison PF, et al. Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. J Neurosurg 2005;102:90-97.
25. Lonser RR, Corthesy ME, Morrison PF, Gogate N, Oldfield EH. Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates. J Neurosurg 1999;91:294-302.
26. Lieberman DM, Corthesy ME, Cummins A, Oldfield EH. Reversal of experimental parkinsonism by using selective chemical ablation of the medial globus pallidus. J Neurosurg 1999;90:928-934.
27. Heiss JD, Walbridge S, Morrison P, et al. Local distribution and toxicity of prolonged hippocampal infusion of muscimol. J Neurosurg 2005;103:1035-1045.
28. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-595.
29. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362-1368.
30. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir (Suppl) 2003;88:105-111.
31. Degen JW, Walbridge S, Vortmeyer AO, Oldfield EH, Lonser RR. Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg 2003;99:893-898.